NEO-ERA-01: A multi-center, single-arm, phase II study with neoadjuvant therapy of HAIC (GEMOX) combined with adebrelimab and lenvatinib for resectable intrahepatic cholangiocarcinoma with high-risk recurrence factors.

Authors

Jing Huang (ORCID: https://orcid.org/0000-0002-0638-4805)
Haipeng Jiang (ORCID: https://orcid.org/0000-0002-1160-1763)
Wei Xu (ORCID: https://orcid.org/0000-0003-4208-7477)
Feng Cheng (ORCID: https://orcid.org/0000-0003-2982-9675)
Jianhua Rao (ORCID: https://orcid.org/0000-0003-1222-7707)
Xuan Xiao
Xin Mu (ORCID: https://orcid.org/0000-0001-5184-7496)
Long Zhang (ORCID: https://orcid.org/0000-0001-8139-0474)
Jin‐Guo Xia
Ye Fan (ORCID: https://orcid.org/0000-0002-8752-5883)
Yong Yang (ORCID: https://orcid.org/0000-0002-1514-722X)
Tao Wang (ORCID: https://orcid.org/0000-0003-4948-9073)
Yuan Cheng (ORCID: https://orcid.org/0000-0003-4173-293X)
Feipeng Zhu (ORCID: https://orcid.org/0000-0002-7885-7544)
Yongquan Chi (ORCID: https://orcid.org/0009-0000-3509-0315)
Ling Lü (ORCID: https://orcid.org/0009-0007-9879-2980)
Wentao Wang (ORCID: https://orcid.org/0000-0001-7749-0026)

Institutions

Xuzhou Medical College (CN)
Sichuan University (CN)
Nanjing General Hospital of Nanjing Military Command (CN)
West China Hospital of Sichuan University (CN)
Ningbo Medical Center Lihuili Hospital (CN)
Jiangsu Province Hospital (CN)
Nanjing Medical University (CN)
Nanjing University (CN)

Publication Details

Journal: Journal of Clinical Oncology
Published: 2025-05-28
DOI: https://doi.org/10.1200/jco.2025.43.16_suppl.e16294
Citations: 1
Primary Topic: Cholangiocarcinoma and Gallbladder Cancer Studies
Type: article
Field-Weighted Citation Impact: 2.01

Controls

|||

ALL TIME

JAN

FEB

MAR

APR

MAY

JUN

JUL

AUG

SEP

OCT

article

NEO-ERA-01: A multi-center, single-arm, phase II study with neoadjuvant therapy of HAIC (GEMOX) combined with adebrelimab and lenvatinib for resectable intrahepatic cholangiocarcinoma with high-risk recurrence factors.

Jing Huang, Haipeng Jiang, Wei Xu, Feng Cheng et al.

May 28, 2025

1 citations

Journal of Clinical Oncology

Cholangiocarcinoma and Gallbladder Cancer Studies

2.01

article

NEO-ERA-01: A multi-center, single-arm, phase II study with neoadjuvant therapy of HAIC (GEMOX) combined with adebrelimab and lenvatinib for resectable intrahepatic cholangiocarcinoma with high-risk recurrence factors.

Jing Huang, Haipeng Jiang, Wei Xu, Feng Cheng, Jianhua Rao, Xuan Xiao, Xin Mu, Long Zhang, Jin‐Guo Xia, Ye Fan, Yong Yang, Tao Wang, Yuan Cheng, Feipeng Zhu, Yongquan Chi, Ling Lü, Wentao Wang

May 28, 2025article en

1 citations

Abstract

No abstract available for this paper.

Journal of Clinical OncologyVol. 43(16_suppl)

Xuzhou Medical College (CN), Sichuan University (CN), Nanjing General Hospital of Nanjing Military Command (CN), West China Hospital of Sichuan University (CN), Ningbo Medical Center Lihuili Hospital (CN), Jiangsu Province Hospital (CN), Nanjing Medical University (CN), Nanjing University (CN)

Openalex Percentile: Top 15%

Cholangiocarcinoma and Gallbladder Cancer Studies

2.01

DOI Source OpenAlex

AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.

NEO-ERA-01: A multi-center, single-arm, phase II study with neoadjuvant therapy of HAIC (GEMOX) combined with adebrelimab and lenvatinib for resectable intrahepatic cholangiocarcinoma with high-risk recurrence factors. — Jing Huang, Haipeng Jiang, et al. · Journal of Clinical Oncology (2025) | TGRS Research Map | TGRS